Abstract:Background In all countries HCV among prisoners has a higher prevalence than in the general population. Specific models of screening and linkage to care are needed to improve the care cascade. Methods The SIcilian Network for Therapy, Epidemiology and Screening In Hepatology (SINTESI) run an HCV point-of-care project in all 23 prisons of Sicily.All prisoners received information on HCV screening and the possibility of receiving treatment with Direct Acting Antiviral (DAA) while incarcerated. HCV status was assessed by screening all subjects for anti-HCV by rapid oral test (OraQuick HCV) and immediate reflex testing for HCV-RNA (GeneXpert-HCV Viral Load, Cepheid). HCV RNA positive subjects received DAA therapy within 72 hours of screening. All prisoners signed an informed consent to use personal data. Chi-square test was used to analyze differences between groups Result Among 5,912 prisoners (98% of prison population) informed of the screening project, 4,911 (83%) accepted to undergo HCV testing. The mean age was 42 years (range 18-86) and 95.8% was males. Non-Italian origin accounted for 12.2% of prisoners (3.7% other EU countries, 7.5% Africa, 0.6% Asia and 0.2% South America). Overall, 245 subjects (5%) testes anti HCV positive, with a prevalence of 4.9% among males and 6.7% among females (p=0.25). We evaluated the risk of drug addiction in subjects with HCV infection in a prison. A prevalence of 25% (25/99) was found among PWUDs on opioid substitution, as compared to 2.9% (30/1,040) in non-PWUDs (p<0.0001). Among 245 anti HCV positive prisoners, 20 refused to be tested for HCV-RNA, 100 tested negative (80 had a history of viral clearance under previous DAA treatment while 20 did not report previous therapy for HCV) and 125 were HCV-RNA positive. Twelve of the latter refused treatment, while 113 started a cycle of DAAs while incarcerated. Among 56 subjects assessable for SVR, 55 (98%) obtained HCV clearance. Conclusions In Sicily, HCV infection is 4 times more common among people in prison than in the general population mostly due to parenteral drug use. Half of the prisoners with a positive screening were unaware of their HCV status and only 32% had received DAAs previously. A one-shot HCV test-and-treat point-of-care approach is highly effective in this setting.

Hepatitis C treatment outcome among people in prison: The SToP‐C study

Treatment effectiveness and side effects of patients with hepatitis C in the prisons of Southern Taiwan: a real-life retrospective analysis

Hepatitis C treatment strategies in prisons: A cost-effectiveness analysis

Understanding hepatitis C virus (HCV) health literacy and educational needs among people in prison to enhance HCV care in prisons

Chronic Hepatitis C Cascade of Care in Prisoners—Is There Still Some Work to Do? Analysis of Two Large Penitentiaries in Northern Italy

Care Navigation Increases Initiation of Hepatitis C Treatment After Release From Prison in a Prospective Randomized Controlled Trial: The C-LINK Study

Real-life data of hepatitis C treatment with direct acting antiviral therapy in persons injecting drugs or on opioid substitution therapy

Perceived access to opioid agonist treatment in prison among people with a history of injection drug use: A qualitative study

Prevention of Mother‐to‐child Transmission of Hepatitis B Virus by Treating Mothers with High Viral Loads

Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C

Eliminating HCV infection from prisons in sicily: the SINTESI project

Expanding Hepatitis C Virus Treatment in the New Mexico State Prison System: Using the ECHO Model for Provider and Prison Peer Education

Hepatitis C virus antiviral drug resistance and salvage therapy outcomes across Australia

HCV‐HIV co‐infection in people who inject drugs: Barriers to treatment and cure of HCV infection in the era of DAAs, a prospective study in Athens, Greece

Chronic hepatitis C elimination prison initiative: HCV-intensive test and treat, a whole prisoner population HCV test-and-treat program in England

Injecting practices during and after hepatitis C treatment and associations with not achieving cure among persons who inject drugs

Disparities in Treatment with Direct-Acting Hepatitis C Virus Antivirals Persist Among Adults Coinfected with HIV and Hepatitis C Virus in US Clinics, 2010–2018

A comparison of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for the treatment of hepatitis C infection among people who inject drugs

Retrospective Study Demonstrating High Rates of Sustained Virologic Response After Treatment With Direct-Acting Antivirals Among American Indian/Alaskan Natives

Direct-Acting Antiviral Treatment Failure Among Hepatitis C and HIV–Coinfected Patients in Clinical Care

Challenges and facilitators in repeated bio-behavioural surveys for blood-borne virus infections in Australian prisons